Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liberty-AD-HAFT Dupixent in Moderate-to-Severe Atopic Hand and Foot Dermatitis
jRCT2031200441Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial in atopic dermatitis (AD) comparing Dupixent every 2 weeks with Placebo every 2 weeks (2 arms). Primary endpoint: IGA hand and foot response at week 16. Started Jun 2021; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031200441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200441.